PuSH - Publication Server of Helmholtz Zentrum München: GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Abd-Ellah, A.* ; Voogdt, C.* ; Krappmann, D. ; Möller, P.* ; Marienfeld, R.B.*

GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.

Sci. Rep. 8:1352 (2018)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Glycogen synthase kinase 3 beta (GSK3 beta) is a ubiquitously expressed serine/threonine kinase involved in the regulation of various cellular functions, such as energy homoeostasis, cell growth and developmental processes. More recently, GSK3 beta has been identified as a part of a protein complex involved in the regulation of the CARMA1-BCL10-MALT1 complex (CBM complex) formation, which is a key signalling event upon antigen receptor engagement of B and T cells, required for the activation of the NF-kappa B and JNK pathways. However, conflicting reports have been published regarding the role of GSK3 beta for the activation of the NF-kappa B signalling pathways. Therefore, we aimed to determine the impact of GSK3 beta on the NF-kappa B signalling induced upon T cell activation. Blocking GSK3 beta by either pharmacologic inhibitors (SB216763 and SB415286) or by RNAi caused a reduced proteolysis of the MALT1 targets CYLD1, BCL10 and RelB as well as diminished I kappa B alpha degradation, NF-kappa B DNA binding and NF-kappa B activity. This negative effect on NF-kappa B appears to be due to a diminished CBM complex formation caused by a reduced BCL10 phosphorylation. Taken together, we provide here evidence for a novel regulatory mechanism by which GSK3 beta affects NF-kappa B signalling in activated T cells.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

4.122

1.245